RxDoctor Payments Data

Connie Dupre, MD

Internal Medicine · Fayetteville, GANPI 1023121381

Payments from drug & device makers

$2,610in general payments, 2019–2025

Across 145 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$355
  • AbbVie$339
  • Lilly USA, LLC$324
  • Pfizer$244
  • AstraZeneca$209
  • Amgen$183
  • plus $956 from 17 others

What the payments were for

  • Food & beverage$2,59699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,610 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$151,405
Medicare patients
447
Services billed
2,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide161$211,883
JardianceEmpagliflozin200$211,557
JanuviaSitagliptin Phosphate183$184,295
EliquisApixaban81$85,481
MounjaroTirzepatide42$58,135
FarxigaDapagliflozin Propanediol55$57,793
TradjentaLinagliptin60$50,116
XareltoRivaroxaban29$37,573
GemtesaVibegron21$22,476
MyrbetriqMirabegron17$18,759
LinzessLinaclotide16$11,632
Breo ElliptaFluticasone/Vilanterol24$11,378
Tresiba Flextouch U-100Insulin Degludec27$10,276
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$9,789
SynthroidLevothyroxine Sodium73$7,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$94$261,673260 claims
Novo NordiskOzempic$355$211,883161 claims
PfizerEliquis$244$85,48181 claims
AstraZenecaFarxiga, Symbicort$209$62,71175 claims
Lilly USA, LLCMounjaro$324$58,13542 claims
Johnson & JohnsonXarelto$24$37,57329 claims
Sumitomo Pharma America, Inc.Gemtesa$128$22,47621 claims
AbbVieLinzess, Synthroid$339$19,04689 claims
Astellas Pharma US IncMyrbetriq$35$18,75917 claims
GSKBreo Ellipta$101$11,37824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Fayetteville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →